



## REGENXBIO to Participate in Upcoming Investor Conferences

November 22, 2022 12:05 PM EST

ROCKVILLE, Md., Nov. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

**Piper Sandler 34th Annual Healthcare Conference**

**Presentation Date:** Thursday, December 1, 2022

**Presentation Time:** 9:10 a.m. ET

**Location:** Lotte New York Palace, New York, NY

**BofA Securities 2022 Virtual Biotech SMID Cap Conference**

**Fireside Chat Date:** Thursday, December 8, 2022

**Fireside Chat Time:** 10:50 a.m. ET

Live webcasts of the presentations can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the webcasts will be available for approximately 30 days following the presentation.

## About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

**Contacts:**

Dana Cormack  
Corporate Communications  
[dcormack@regenxbio.com](mailto:dcormack@regenxbio.com)

**Investors:**

Chris Brinzey, ICR Westwicke  
339-970-2843  
[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301684731.html>

SOURCE REGENXBIO Inc.